Nom du produit:3-phenyl-1H-pyrazole-4-carbaldehyde

IUPAC Name:3-phenyl-1H-pyrazole-4-carbaldehyde

CAS:26033-20-5
Formule moléculaire:C10H8N2O
Pureté:95%+
Numéro de catalogue:CM112605
Poids moléculaire:172.19

Unité d'emballage Stock disponible Prix($) Quantité
CM112605-5g in stock ǫŸ
CM112605-10g in stock ƚƴŸ
CM112605-25g in stock ƐȖŪ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:26033-20-5
Formule moléculaire:C10H8N2O
Point de fusion:-
Code SMILES:O=CC1=CNN=C1C2=CC=CC=C2
Densité:1.248±0.06 g/cm3
Numéro de catalogue:CM112605
Poids moléculaire:172.19
Point d'ébullition:421.7°C at 760 mmHg
N° Mdl:MFCD00216971
Stockage:Keep in Inert atmosphere, store at 2-8°C.

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Lazertinib
Johnson & Johnson announced new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations. These data showed a comparable response rate in patients treated with SC amivantamab and lazertinib compared to those treated with the intravenous (IV) formulation in the MARIPOSA study, which established the combination of amivantamab and lazertinib as superior to osimertinib. Lazertinib is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.